MDM2 inhibitors, a new anticancer drug developed by Hudson, a subsidiary of Hainan Haiyao, is undergoing preclinical research

Hainanhai Pharmaceutical Co., Ltd said on April 14 that its holding subsidiary Hudson biomedical Co., Ltd., which holds 70% of the shares, is still in the pre clinical research stage of new anti-cancer drugs If the product is put into production, it needs to go through preclinical research, apply for clinical approval from FDA, enter into clinical experiments, and according to the results of clinical experiments, FDA will give the drug production approval before it can be put on the market At present, the time and result of obtaining production approval are uncertain According to new drug collection, Hudson's independently developed new compounds (spiroindolino NES as MDM2 inhibitors) obtained the patent license acceptance certificate from the U.S patent and Trademark Office in September 2014 Data show that MDM2 inhibitors are a new type of MDM2 inhibitors with high affinity The new compounds reactivate protein p53 by blocking the interaction between MDM2 and p53 P53 is a precise regulatory factor in human body, also known as "tumor killing shadow", and it is a guard to maintain the integrity of cell genes Almost all cancers are related to the loss of p53 function MDM2 inhibitors is a significant breakthrough in the treatment of cancer, and has a broad application prospect in the treatment of cancer, retinal macular degeneration and other diseases related to p53 Hudson biomedical Co., Ltd (USA), registered in New Jersey science and Technology Park, is mainly engaged in the research of original drugs, improvement of current product process and guidance of chemical synthesis, collection of international pharmaceutical market information and research market dynamics, and prospective research on products, technology and market